Previous 10 | Next 10 |
2024-02-28 08:03:13 ET DENVER, Colo., Feb 28, 2024 ( 247marketnews.com )- Incannex Healthcare Inc. (NASDAQ: IXHL ) reported, this morning, positive topline results from its psilocybin in generalized anxiety disorder (GAD) Phase 2 Psi-GAD1 clinical trial, and that the trial met its p...
Highlights: PsiGAD1 trial achieves primary endpoint; PsiGAD psilocybin-assisted therapy demonstrated a statistically significant HAM-A reduction of 12.8 points from baseline, representing a 9.2-point improvement over psychotherapy with placebo (p <0.0001), exceeding the company...
A look at the top 10 most actives in the United States Greenbrook TMS Inc. (GBNH) rose 64.9% to $0.32 on volume of 109,974,769 shares PROSHARES TRUST (SQQQ) rose 3.7% to $12.36 on volume of 106,443,308 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 4.7% to $4.825 on volume...
2024-02-21 12:27:34 ET More on Mid-day movers & stocks. Janux Therapeutics: Precision Immunotherapy, But Overpriced For Such An Early Stage Greenbrook TMS secures $1.5M in debt financing Compass Pathways and Greenbrook TMS enter into three-year research collabora...
MELBOURNE, Australia and NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex or the Company), a leading cannabinoid and psychedelic medicine biotechnology company, is pleased to announce the successful completion of a pre-IND (Investigational N...
Highlights: Clarion’s Head of Psychiatry, Professor Suresh Sundram, has been approved by the TGA to prescribe MDMA for Post-traumatic Stress Disorder and psilocybin for Treatment-resistant Depression, alongside extensive psychotherapy. Clarion Clinics’ built-for-purpos...
MELBOURNE, Australia and NEW YORK, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex’ or the ‘Company’), a pharmaceutical company developing novel medicinal cannabinoid pharmacotherapies and psychedelic medicine therapies for un...
Highlights: 72 patients treated at purpose-built facilities within Monash University, Melbourne, Australia. Topline results from the trial anticipated within current Q1 2024. FDA IND application is well-advanced after commencing preparations in August, 2023. Independent docu...
MELBOURNE, Australia and NEW YORK, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex’ or the ‘Company’), a pharmaceutical company developing unique medicinal cannabinoid pharmacotherapies and psychedelic medicine thera...
2023-12-28 12:33:33 ET Summary Incannex Healthcare Inc. is a developer of medicinal cannabinoid and psychedelic pharmaceutical products. Their strategy is to combine cannabinoid drugs with patent-expired therapeutic compounds for better therapeutic effects. They have several p...
News, Short Squeeze, Breakout and More Instantly...
Incannex Healthcare Limited Company Name:
IXHL Stock Symbol:
NASDAQ Market:
Incannex Healthcare Limited Website:
NEW YORK and MELBOURNE, Australia, May 30, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex’ or the ‘Company’), a pharmaceutical company developing unique medicinal cannabinoid pharmacotherapies and psychedelic medicine therapies is ple...
Incannex Healthcare Inc. (IXHL) is expected to report for Q3 2024
MELBOURNE, Australia and NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex or the Company), a leading cannabinoid and psychedelic medicine biotechnology company, is pleased to announce the successful completion of a pre-IND (Investig...